S elective serotonin-reuptake inhibitors (SSRIs) are firstline drugs for treatment of depression and anxiety disorders 1,2 and represent one of the most frequently prescribed drugs in developed countries. 3 Within the last twenty years, the use of antidepressants has markedly increased, especially the prescription of SSRIs, which demonstrated a comparable Background and Purpose-Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage-an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. Methods-A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4. 
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December 2017 efficacy and a better tolerability than tricyclic antidepressants. 3 However, there are persisting concerns on the association of SSRIs with major bleeding events, [4] [5] [6] [7] which may be further increased when concomitant antithrombotics are prescribed. The presumed mechanism underlying this association is that SSRIs decrease the amount of serotonin released by platelets, which plays an important role in platelet aggregation. 6 Although the association between SSRI use and abnormal bleeding has most consistently been demonstrated for the gastrointestinal tract, 8, 9 there is accumulating evidence for a link between SSRIs and cerebral bleeding. Indeed, treatment with SSRIs seems to confer an increased risk of developing cerebral microbleeds. 10 Moreover, a meta-analysis of observational studies and a recent large population-based cohort study suggested that the risk of spontaneous intracranial hemorrhage is ≈1.5-fold higher in patients treated with SSRIs. 11, 12 However, it is currently unknown whether preexisting treatment with SSRIs increases the risk of post-thrombolysis symptomatic intracerebral hemorrhage (sICH) in patients with acute ischemic stroke-a complication entailing a strong risk of early mortality and unfavorable functional outcome. 13 Therefore, we sought to assess whether preadmission treatment with SSRIs is associated with an increased risk of sICH and unfavorable functional outcome after thrombolysis for acute ischemic stroke, taking into account potential interaction with concomitant use of antithrombotics.
Methods
On request, we will make the data, methods, and study materials available to other researchers for analysis at the Department of Neurology, Charité, Berlin. The corresponding author will keep a copy of the final data set for at least 10 years. Data sharing will be restricted to non-commercial and academic purposes only. Data ownership remains at the center that originally obtained the data. The centers will have to give permission for re-use of the data.
Data Source, Design, and Patients
This cohort study was conducted under the auspices of the TRISP (Thrombolysis in Ischemic Stroke Patients) collaboration. We pooled data from 7 dedicated European stroke centers that operate prospective registries of patients treated with intravenous thrombolysis (IVT; list of collaborators in the online-only Data Supplement). Data from individual patients were collected by local investigators using a standardized form with predefined variables (list in Methods in the online-only Data Supplement), as performed in previous collaborative TRISP studies. 14, 15 The period of data collection for each participating center ranged from 1998 to 2016 (Table I in the online-only Data Supplement). All patients with ischemic stroke aged ≥18 years treated with IVT (alteplase) within the 4.5-hour time window and for whom core data on preadmission medication, age, sex, baseline National Institutes of Health Stroke Scale score, and sICH was available were eligible for analysis. Patients treated by IVT followed by endovascular thrombectomy were also included. Patients taking oral anticoagulants (OACs) were included if international normalized ratio before thrombolysis was <1.7. 16 In patients treated with direct OACs, the decision to treat was based according to time of last intake (>2 days) or normal specific coagulation tests according to the discretion of the respective stroke physician. 16, 17 Patients with unknown time of symptom onset were not considered eligible because of different treatment protocols at the respective sites.
Approval of each center's Ethics Committees to maintain a prospective registry of patients with acute stroke treated with IVT was obtained according to local regulations.
Use of SSRI and Outcomes
Data on treatment with antidepressants were retrospectively collected from medical records. Antidepressants with anatomic therapeutic chemical code N06AB (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline) were classified as SSRIs, whereas other antidepressants were labeled non-SSRIs. 18 For the main analysis, the control group consisted of all patients not using SSRIs. Subsequently, sensitivity analyses excluding those patients taking non-SSRI antidepressants were conducted.
Outcomes were prospectively collected. The main outcome was occurrence of sICH according to ECASS II criteria (European Cooperative Acute Stroke Study; any intracerebral hemorrhage associated with an increase in the National Institutes of Health Stroke Scale score of at least 4 points within 36 hours after thrombolysis). 19 Secondary outcome was unfavorable functional outcome (mRS >2) at 3 months, assessed by using a structured interview at outpatient visits or telephone calls with patients or relatives. 14, 20 
Statistical Methods
The methods used for descriptive statistics are detailed in the Methods in the online-only Data Supplement. Associations between sICH or unfavorable outcome and preadmission treatment with SSRIs were assessed by calculation of unadjusted and adjusted odds ratios (ORs) with 95% confidence interval (CI) in binary logistic regression models. All variables associated with the dependent variable (sICH or unfavorable outcome) at a level of P<0.10 in univariable analysis were included in multivariable models, except (1) for variables with ≥10% missing data (statins; renal function) and (2) in case the inclusion of correlated variables would induce relevant multicollinearity within the model, defined as the largest condition index ≥30. 21 The proportion of variation in the dependent variable that was explained by each logistic model was estimated by calculating R 2 values.
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Because the use of antithrombotics may modify the association between SSRI and abnormal bleeding, 8, 11, 12 the assessment of potential interactions between OAC or antiplatelet use and SSRI was prespecified and performed using the Breslow-Day test. Additional analyses were subsequently conducted to permit evaluation of interaction on both an additive and a multiplicative scale. 23 Finally, sensitivity analyses were conducted (Methods in the online-only Data Supplement for details).
Results
A total of 6293 patients met the inclusion criteria. Fifty-one patients were excluded because of missing data on the primary outcome, leaving 6242 patients for the main analysis (mean age, 70.1±14.0 years; 43.9% women; median National Institutes of Health Stroke Scale, 9; interquartile range, 5-16). Preadmission treatment with SSRIs at the time of thrombolysis was documented in 266 (4.3%) patients. Table 1 shows baseline characteristics of patients according to preadmission use of SSRIs.
Frequency of sICH
Frequency of SICH was 3.9% (95% CI, 3.5%-4.4%; n=244) and was not different among patients with and without preadmission use of SSRIs (4.9%; 95% CI, 2.9%-8.2% versus 3.9%; 95% CI, 3.4%-4.4%; unadjusted OR, 1.28; 95% CI, 0.72-2.27; P=0.40). 
Interaction Between SSRIs and Antithrombotic Drugs on Frequency of sICH
A total of 233 patients received OAC before IVT, including 21 patients treated with direct OACs. There was a significant interaction effect between use of SSRI and OAC on occurrence of sICH (P for interaction, 0.01). To permit further evaluation of interaction on an additive scale, we analyzed the frequency of sICH according to 4 different exposure groups, based on SSRI or OAC use (Table 3 ). Frequency of sICH in patients taking both SSRI and OAC was 23.1% (95% CI, 8.2%-50.3%), which would correspond to a number needed to harm of 6 if compared with patients taking OAC only. Concomitant use of SSRI and OAC was significantly associated with sICH, compared with patients using neither drug as reference category (unadjusted OR, 7.65; 95% CI, 2.09-28.00; adjusted OR, 7.37; 95% CI, 1.92-28.35; Table 3 ). Concomitant use of SSRI and OAC was also significantly associated with sICH when patients taking OAC but not SSRIs were used as reference category (unadjusted OR, 6.30; 95% CI, 1.50-26.53; adjusted OR, 9.04; 95% CI, 1.95-41.89).
In a subgroup analysis confined to patients using OACs before stroke (n=233), 13 patients had sICH (overall sICH frequency, 5.6%; 95% CI, 3.3%-9.3%). The rate of sICH was higher in patients taking both SSRIs and OAC than in those solely taking OAC (unadjusted OR, 6.30; 95% CI, 1.50-26.53; P=0.01). This association remained significant after adjustment for concurrent use of antiplatelet drugs (adjusted OR, 5.15; 95% CI, 1.15-23.09; P=0.03). There was no evidence of an interaction effect between use of SSRI and concurrent use of antiplatelets on occurrence of sICH (P for interaction, 0.90). Patients taking both antiplatelet drugs and SSRIs did not have a significantly higher risk of sICH compared with patients taking neither drug (data not shown).
Functional Outcome at 3 Months
Data on functional outcome at 3 months was available in 6013 (96.3%) patients. Unfavorable outcome was observed in 2657 (44.2%) patients. Patients with preadmission use of SSRI were more likely to have an unfavorable outcome EVT indicates endovascular thrombectomy; GFR, glomerular filtration rate; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and SSRI, serotonin-reuptake inhibitors.
*Missing data for the following variables: independent status before stroke (n=50), atrial fibrillation (n=100), hypertension (n=14), diabetes mellitus (n=16), previous stroke (n=21), antithrombotic drug (n=37), statins (n=702), systolic blood pressure (n=306), GFR (n=651), and glucose (n=257). 
Sensitivity Analyses
All results remained similar in sensitivity analyses (Results in the online-only Data Supplement; Table III in the online-only Data Supplement).
Discussion
In this large collaborative study, preadmission use of SSRI was not significantly associated with sICH after IVT for acute ischemic stroke. However, there was a significant interaction between preadmission use of SSRIs and OACs for the occurrence of sICH, and our results suggest a higher rate of sICH among thrombolyzed patients using both drug classes. Another salient finding is that unfavorable functional outcome 3 months after thrombolysis was more frequent in patients taking preadmission SSRIs, even when confounders were taken into account. There is corroborative evidence from observational studies that use of SSRIs confers a higher risk of major bleedings. 6, 8, 9, 11, 12, 24 Our study is the first to shed light on the potential relationship between SSRIs and intracerebral hemorrhage in the distinct clinical setting of IVT for acute ischemic stroke. In this particular setting, the absolute risk of sICH is higher, ≈5% within the first 36 hours after thrombolysis. 20 We did not observe a significantly higher rate of sICH among SSRI users. Altogether, our results suggest that if there is any increased risk of sICH attributable to SSRI use, it is probably small and, therefore, unlikely to exceed the benefits of thrombolysis.
However, our findings suggest that the particular subgroup of patients taking both SSRIs and OAC is at higher risk of post-thrombolysis sICH. Previous studies, conducted in other clinical settings, already suggested that SSRIs confer an increased bleeding risk when associated with antithrombotic drugs. Although concomitant use of SSRIs and antiplatelets mainly increases the risk of gastrointestinal bleedings, possibly via synergistic mechanisms causing local injury to the gastric mucosa, 6, 8 the association of coumarin derivatives and SSRIs has been linked to an increased risk of nongastrointestinal bleeding events. 25 Strikingly, the 2 studies linking SSRIs to spontaneous intracranial hemorrhage mentioned above suggested a substantially higher risk of intracerebral hemorrhage when concomitant use of OAC was present. 11, 12 In accordance with those findings, we observed a significant interaction between SSRIs and OAC, but not antiplatelets, for the risk of sICH. Most importantly, the rate of post-thrombolysis sICH in the subgroup of patients taking both SSRIs and OAC was high (23.1%). Because of small numbers in this subgroup (3 sICH events of 13 patients taking both drugs), these results should be interpreted with caution. However, the interaction between SSRIs and OAC was observed on both a multiplicative and an additive scale, 23 and the findings remain unchanged in several sensitivity analyses. Moreover, the lower boundary of the 95% CI for the frequency of sICH in this subgroup still corresponds to a high bleeding rate (8.2%). Our findings cannot be entirely explained by a pharmacological interaction between SSRIs and OACs via inhibition of CYP2C9 26 because no patient with international normalized ratio >1.7 was included in the present study, in line with current guidelines on thrombolysis for acute ischemic stroke. 16 Because SSRIs and OACs impair primary and secondary hemostasis, our findings seem biologically plausible and remained unchanged after adjustment for the use of antiplatelets. If further studies confirm that patients taking both OACs and SSRIs have a high risk of post-thrombolysis sICH, thrombectomy without prior IVT might be considered in those patients with large-vessel occlusion. 27 However, the present evidence is insufficient to recommend withholding standard-dose IVT in patients who take both SSRIs and OAC. We observed a significant association between preadmission exposure to SSRIs and unfavorable functional outcome at 3 months. At first sight, our findings are conflicting with those of randomized controlled trials, which showed that prescription of SSRIs after ischemic stroke may result in a lower disability, presumably by brain plasticity modulation. 28, 29 However, these trials and the present study were conducted in different patient populations and time settings. For example, patients were not eligible for inclusion in the FLAME trial (Fluoxetine for Motor Recovery After Ischemic Stroke) if they had depressive symptoms, were taking antidepressants during the month before admission, or had substantial prestroke disability. 28 Because of the retrospective design of our study, we do not have data on prestroke depressive symptoms or on the duration of SSRI treatment after thrombolysis. However, it is likely that many patients taking SSRIs in our cohort experienced depression or anxiety, which may reflect more frequent comorbidities. This might in turn explain the higher rates of unfavorable outcome at 3 months. Additionally, history of depression is a strong predictor of poststroke depression, which has been associated with increased disability, cognitive impairment, and mortality. 30, 31 Even though SSRI use was linked to unfavorable outcome in our multivariable analysis, we think that this association is confounded, notably by preadmission depression and comorbidities. Therefore, our data do not support discontinuation of SSRIs during the first 3 months after thrombolysis and may even suggest that more efforts are needed to support this group of patients throughout the early rehabilitation phase, which is critical for functional recovery.
Strengths and Limitations
The strengths of this study involving 7 European stroke centers with long-standing experience in revascularization therapies include its large sample size and the prospective data collection on the outcomes and their respective predictors. However, several potential limitations need to be acknowledged. First, because of the retrospective collection of data on SSRI use, treatment dose and time since drug initiation were not available. Therefore, we could not estimate the proportion of patients who started SSRIs within 30 days, which is a presumed risk factor for abnormal bleeding. 6, 12 Second, our sample size did not allow in-detail subgroup analyses on type or dose of SSRIs. Third, potential confounders that have either been linked to a higher risk of sICH after IVT or bleeding events in SSRI users (eg, cerebral microbleeds or nonsteroidal anti-inflammatory drugs 32, 33 ) were not collected in the present study. In addition, the proportion of the variance in outcomes explained by our models was low. Therefore, residual confounding is possible. Fourth, the majority of included patients is likely of white ethnicity, and further studies are, therefore, needed to ensure that our results could be generalized to other populations.
In summary, we did not observe a significant increase in the risk of sICH after thrombolysis in patients with exposure to SSRIs before ischemic stroke in general. However, we observed a significantly higher rate of sICH in patients using SSRIs and OACs, which suggests that caution seems warranted in this particular subgroup. Still, our findings should be interpreted carefully because only 13 subjects received both SSRIs and OACs. If confirmed, the findings of our study may inform clinical decision making and individual estimation of risks and benefits of thrombolysis for ischemic stroke. For instance, reduced dose IVT or mechanical thrombectomy without bridging thrombolysis in patients with proximal large-vessel occlusion may be considered in patients using SSRI and OAC. 34 Preadmission treatment with SSRIs-a marker of preexisting mood disorders-was associated with unfavorable functional outcome at 3 months. This might indicate that more efforts are needed to support this group of patients throughout the rehabilitation phase.
